Suzetrigine, also known as VX-548, is a selective inhibitor of the voltage-gated sodium channel Nav1.7, being developed by Vertex Pharmaceuticals for the treatment of acute and neuropathic pain. It exhibits potent in vitro inhibition of human Nav1.7 with an IC₅₀ in the low nanomolar range (typically reported around 5–10 nM), while showing over 100-fold selectivity over other Nav isoforms such as Nav1.5 and Nav1.4, minimizing cardiac and skeletal muscle off-target effects. In preclinical studies, VX-548 effectively reduced nociceptive signaling in dorsal root ganglion neurons and demonstrated robust antinociceptive activity in rodent pain models.
MedKoo Cat#: 130057
Name: Suzetrigine
CAS#: 2649467-58-1
Chemical Formula: C21H20F5N3O4
Exact Mass: 473.1374
Molecular Weight: 473.40
Elemental Analysis: C, 53.28; H, 4.26; F, 20.07; N, 8.88; O, 13.52
The following data is based on the product molecular weight 473.40 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
|---|---|---|---|
| 1 mM | 1.15 mL | 5.76 mL | 11.51 mL |
| 5 mM | 0.23 mL | 1.15 mL | 2.3 mL |
| 10 mM | 0.12 mL | 0.58 mL | 1.15 mL |
| 50 mM | 0.02 mL | 0.12 mL | 0.23 mL |
